Objective-TWEAK is a multifunctional cytokine belonging to the tumor necrosis factor superfamily and binds to the receptor Fn14. TWEAK and Fn14 are expressed in atherosclerotic plaques in areas rich in macrophages and foam cells. We investigated the role of TWEAK/Fn14 interactions in ApoE Ϫ/Ϫ mice and bone marrow-derived macrophages in vitro.
T NF-like weak inducer of apoptosis (TWEAK) is a recently identified cytokine of the tumor necrosis factor (TNF) superfamily. 1 It is first synthesized as a type II transmembrane protein in macrophages and other cell types, but usually cleaved into a secreted form. 2 Fibroblast growth factor (FGF)-inducible 14 (Fn14) is widely recognized as the cognate receptor of TWEAK. [3] [4] [5] Although it has been suggested that there are other binding partners for TWEAK, 6 no other ligands for Fn14 have been identified. 1 
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TWEAK is a pleiotropic cytokine initially described as a weak inducer of apoptosis. Multiple pathways of TWEAKinduced cell death through Fn14 have since been reported, 2, 7, 8 however the signaling pathway for cell death is not fully understood. Binding of TWEAK to Fn14 results in TRAFmediated activation of NF-B thereby regulating genes involved in a variety of processes, many important in atherosclerosis. 9 TWEAK induces the proliferation and migration of endothelial cells (ECs) and aortic smooth muscle cells (SMCs) in vitro. 10, 11 In addition, TWEAK can promote tissue inflammation and remodeling by stimulating the expression of adhesion molecules, proinflammatory cytokines, chemokines, and matrix metalloproteinases (MMPs) in many cell-types. 1, 12 Analysis of human atherosclerotic plaques showed that TWEAK and Fn14 are expressed in areas rich in macrophages, foam cells, and SMCs. 13, 14 In a recent study, reduced levels of TWEAK were identified in the plasma of atherosclerosis patients and asymptomatic subjects with increased intima-media thickness as compared to healthy subjects. 15 The effects of the TWEAK/Fn14 pathway on atherogenic development, however, have not yet been determined. In the present study, we used a soluble Fn14-Fc fusion protein to block TWEAK in a mouse model of atherosclerosis and report effects on development of advanced plaques in vivo and decreased lipid uptake by macrophages in vitro.
Materials and Methods
We performed an in vivo intervention study in which chow-fed ApoE Ϫ/Ϫ mice were injected intraperitoneally twice a week with 100 g of Fn14-Fc or isotype control Ab (P1.17). Mice received treatment for 12 weeks beginning at either 5 weeks of age when no atherosclerotic lesions were present in the aortic arch (early treatment: Fn14-Fc nϭ15, control nϭ15) or 17 weeks of age when advanced lesions began to appear in the aortic arch (delayed treatment: Fn14-Fc nϭ14, control nϭ14). Aortic arch atherosclerotic lesions were classified as either initial (fatty streaks, containing macrophage-derived foam cells) or advanced (containing extracellular lipid, a lipid core, or a fibrous cap). Lesion area and composition were assessed using histology, morphometry, and immunohistochemistry. For in vitro studies, bone marrow-derived macrophages were isolated from ApoE Ϫ/Ϫ mice and the following experiments were performed: assessment of Fn14 expression, lipid uptake, cholesterol efflux, apoptosis and migration, cytokine secretion, and scavenger receptor expression. All materials and methods are detailed in the supplement (available online at http://atvb.ahajournals.org).
Results

General
Average body weight did not differ in Fn14-Fc-treated mice compared to controls with either the early or delayed treatment regiment. There were also no differences in plasma total cholesterol, triglycerides, or LDL, although HDL was slightly elevated in mice receiving early Fn14-Fc-treatment (Table) . Autopsy of organs revealed no abnormalities or pathologies.
Analysis of Fn14-Fc levels showed that, in both treatment regimens, Fn14-Fc serum concentrations were at least 12 g/mL after 1 week and were maintained in the range of 4 to 46 g/mL throughout the course of the experiments.
Fn14-Fc Treatment Diminished Plaque Progression From the Initial to the Advanced State
Early Fn14-Fc treatment of ApoE Ϫ/Ϫ mice starting at 5 weeks of age resulted in smaller advanced plaques compared to control ( Figure 1A ). The number of initial and advanced plaques, however, did not differ between Fn14-Fc-and control-treated mice (initial lesions 3.7Ϯ0.3 versus 3.4Ϯ0.3, advanced lesions 0.5Ϯ0.2 versus 1.3Ϯ0.4 in Fn14-Fc-and control-treated mice, respectively). In the delayed treatment group, however, there were more initial plaques and fewer advanced plaques in Fn14-Fc-treated mice compared to controls (initial lesions 2.9Ϯ0. 5 
Fn14-Fc Treatment Reduced Plaque Fibrotic Content and Decreased Macrophage Size
Fn14-Fc treatment not only reduced advanced plaque size and number, but also altered the composition of lesions. Both early and delayed Fn14-Fc treatment resulted in less fibrous plaques, as indicated by reduced ␣-smooth muscle actin (␣SMA) content in both initial and advanced lesions in the delayed treatment group (Figure 2A ), as well as reduced collagen in advanced plaques in both the early and delayed treatment groups ( Figure 2B ).
Macrophage and leukocyte content was also modulated by delayed Fn14-Fc treatment. CD45ϩ cell content, reflecting leukocyte infiltration, was decreased in initial plaques (percentage of CD45ϩ cells relative to total cells in the lesions: 6.8Ϯ1.3% versus 3.8Ϯ0.6% in control and Fn14-Fc-treated animals, respectively. Pϭ0.009) but not altered in advanced plaques after delayed Fn14-Fc treatment (percentage of CD45ϩ cells relative to total cells in the lesions: 2.3Ϯ0.3% versus 2.5Ϯ0.4% in Fn14-Fc and control-treated animals, respectively). Interestingly, macrophage content was increased in advanced plaques by delayed Fn14-Fc as compared to control treatment ( Figure 2C ), and these macrophages were smaller than in controls ( Figure 2E ). No lipid cores were observed in the early treatment group; lipid core sizes in advanced plaques were relatively small and did not differ between Fn14-Fc-and control-treated mice with the delayed treatment regiment ( Figure 2D ). Thus, Fn14-Fc treatment affected several features of the advanced atherosclerotic lesions in ApoE Ϫ/Ϫ mice. Advanced plaques were less fibrotic, rich in macrophages relative to CD45ϩ cells, and contained smaller macrophages without a change lipid core size.
Fn14 Is Expressed by Macrophages and Foam Cells
To ascertain whether the Fn14 receptor is expressed by macrophages and foam cells, immunolabeling was performed 
TWEAK/Fn14 Interactions Did Not Affect Apoptosis in Macrophages In Vitro and in the Lesions In Vivo
The increased macrophage numbers in advanced lesions might be attributable to a reduction in apoptosis with Fn14-Fc treatment. Therefore, apoptosis was determined in ApoE Ϫ/Ϫ macrophages and foam cells in vitro after treatment with TWEAK. Because endogenous TWEAK might be affecting the baseline apoptosis under these culture conditions, the effects on apoptosis of various reagents that block TWEAK/Fn14 interactions, including Fn14-Fc, anti-Fn14 antibody, and anti-TWEAK antibody, were also determined. As shown in Figure  4A , neither TWEAK nor TWEAK-blocking reagents had any effect on apoptosis of macrophages and foam cells.
Because the costimulation of several apoptotic pathways is frequently required to demonstrate effects on apoptosis, ApoE Ϫ/Ϫ macrophages were costimulated with TWEAK plus TNF, and TWEAK plus cycloheximide. It was found that when cells were costimulated with TWEAK and TNF, apoptosis was elevated (9.1Ϯ0.43%) compared to stimulation with TNF alone (5.75Ϯ0.15%, PϽ0.05), or TWEAK alone (6.4Ϯ0.51%, PϽ0.05) (supplemental Figure I) .
To further ascertain the effects of Fn14-Fc on macrophage apoptosis, TUNEL staining was performed on aortic arch sections containing atherosclerotic plaques. The number of TUNELϩ cells in Fn14-Fc-treated mice did not differ from those in controls in either the early or delayed treatment groups ( Figure 4B ). These data suggest that TWEAK/Fn14 interactions alone did not mediate apoptosis of macrophage foam cells in vitro, and Fn14-Fc treatment in vivo did not affect apoptotic rates in atherosclerotic plaques.
TWEAK Blockade Altered Macrophage Trafficking
Another potential mechanism for the increased macrophage numbers in the lesions of Fn14-Fc-treated mice is altered macrophage migration. Two experimental conditions were used to test this possibility. In one condition, bone marrowderived ApoE Ϫ/Ϫ macrophages were treated with TWEAK, anti-TWEAK Ab, or control Ab and allowed to migrate across a transwell membrane toward complete medium (supplemental Figure IIA, top) . This condition revealed no effect of TWEAK or anti-TWEAK Ab on cell migration as compared to P1.17, their matched control Ab (supplemental Figure IIB) . In the second condition, the macrophages were suspended in both the upper and lower chambers, and those in the lower chamber treated with TWEAK, anti-TWEAK Ab, or control Ab to determine the effect of localized treatment on macrophage distribution, with cells from either chamber migrating into the membrane. Treatment of cells with TWEAK in bottom chambers reduced the number of migrated cells as compared with control Ab and cells treated with anti-TWEAK Ab. Conversely, treatment with anti-TWEAK in the bottom chamber significantly increased the number of migrated cells as compared to the control Ab (supplemental Figure IIB) . This suggests that blocking TWEAK may alter monocyte trafficking.
TWEAK Blockade Decreased Lipid Uptake by Macrophages
The reduced macrophage size in advanced plaques after delayed Fn14-Fc treatment might be attributable to reduced lipid uptake. This possibility was directly tested in vitro.
Bone marrow-derived ApoE
Ϫ/Ϫ macrophages pretreated with TWEAK or Fn14 blocking reagents contained less DiI-labeled oxLDL compared to cells treated with control antibody after both 10 and 30 minutes of lipid loading ( Figure  5A ). Conversely, addition of TWEAK to the culture did not further enhance lipid uptake (data not shown), suggesting there may already be sufficient endogenous TWEAK in the culture system. These data indicate that endogenous TWEAK/Fn14 interactions regulate lipid uptake in cultured macrophages and may thereby affect the size of macrophages in vivo. Although TWEAK could not be detected in conditioned medium of bone marrow-derived ApoE Ϫ/Ϫ macrophages as determined by ELISA (data not shown), secreted TWEAK may be below the limit of detection or bound to its receptor, or endogenous TWEAK contributing to lipid uptake may be membrane-bound, though we have not been able to confirm reports of cell surface TWEAK expression 7 (Linda C. Burkly, Biogen Idec, unpublished observations 2009). Alternatively, intracellular TWEAK activity independent of Fn14 has been suggested, 16 however we consider this to be unlikely because the lipid uptake was also regulated by Fn14.
To further substantiate that blocking TWEAK reduces macrophage lipid uptake in vitro, we determined its effect on cholesterol efflux in bone marrow-derived ApoE Ϫ/Ϫ macrophages in vitro. The cholesterol acceptor HDL was used to determine ABCG1 and SR-B1-mediated cholesterol efflux, whereas the cholesterol acceptor D37F (a specific ApoA-1 peptide mimetic) was used to determine ABCA1-mediated cholesterol efflux. 17 Anti-TWEAK blocking mAb did not affect cholesterol efflux compared with control Ab treatment nor was there any effect of Fc-TWEAK as shown in Figure  5B and 5C. Thus blocking TWEAK appeared to reduce lipid uptake ( Figure 5A ) without affecting lipid efflux.
TWEAK Blockade Did Not Affect Cytokine Excretion by Macrophages
We also studied the effect of the TWEAK pathway on proinflammatory cytokine production by macrophages. Addition of oxLDL to macrophages decreased IL-10 secretion and adding TWEAK or anti-TWEAK with oxLDL had no effect on IL-10 secretion compared with control Ab (supplemental Figure III) . The cytokines IL-6, IL-12, and TNF could not be detected in the ox-LDL-treated macrophage cultures in the absence or presence of TWEAK reagents (data not shown).
TWEAK Blockade Did Not Affect Macrophage CD36 and SR-A RNA Expression
We wished to determine whether TWEAK blockade reduced lipid uptake by reducing scavenger receptor expression. Quantitative RNA analysis revealed that treatment of macrophages with oxLDL increased CD36 but had no effect on SR-A expression (supplemental Figure IVA and IVB) . Treating foam cells with anti-TWEAK treatment did not affect scavenger receptor expression as compared to control Ab treatment.
Discussion
In the present study we used an Fn14-Fc fusion protein to block TWEAK/Fn14 interactions and determined its effect on Figure 5 . A, Bone marrow-derived macrophages treated with TWEAK-inhibiting reagents (100 ng/mL Fn14-Fc; 10 g/mL antiFn14 mAb and anti-TWEAK mAb) took up less DiI-labeled oxLDL after 30 minutes of lipid loading compared to control Ab treatment. Black bars refer to TWEAK-inhibiting reagents, and white bars refer to respective control antibodies. y axis is the mean fluorescence intensity (MFI) of DiI-labeled oxLDL uptake for a total of 10 4 cells. *PϽ0.05. B, ABCG1 and SR-B1-mediated cholesterol efflux in ApoE Ϫ/Ϫ macrophages increased with HDL as an acceptor (final concentration HDL: 5, 10, and 20 g/mL). There was no significant effect of treatment with anti-TWEAK or Fc-TWEAK on cholesterol efflux as compared to control Ab treatment (P1.17). C, ABCA-1-mediated cholesterol efflux in ApoE Ϫ/Ϫ macrophages increased with D37F as an acceptor (final concentration D37F: 2.5 and 5 g/mL). There was no significant effect of treatment with anti-TWEAK or Fc-TWEAK on cholesterol efflux as compared to control Ab treatment (P1.17).
lesion development and progression in the ApoE
Ϫ/Ϫ mouse atherosclerosis model. Our novel findings revealed no effect on plaque initiation, but rather that the TWEAK/Fn14 pathway regulated atherosclerosis at later stages. Fn14-Fc treatment affected the development of advanced plaques, resulting in reduced size (early treatment), number (delayed treatment), and fibrotic content (early and delayed treatment). Delayed treatment did not alter overall leukocyte content in advanced lesions but increased the abundance of macrophages with smaller macrophage size. Blocking TWEAK reduced macrophage uptake of modified lipids in vitro. Thus, TWEAK/Fn14 pathway appears to promote atherosclerosis and may promote macrophage lipid uptake in ApoE Ϫ/Ϫ mice. The alterations induced by Fn14-Fc treatment are consistent with an inhibition of plaque progression, and may be attributable to inhibition of the effects of TWEAK on the macrophages and SMC both of which express Fn14. However, Fn14-Fc also induced a unique advanced plaque phenotype rich in small macrophages. Given the uniqueness of this finding, we focused on the mechanistic basis, assessing TWEAK/Fn14 regulation of macrophage apoptosis, migration, inflammatory activity, and lipid uptake.
Blocking the TWEAK/Fn14 pathway may have reduced apoptosis of macrophage foam cells in lesions resulting in their accumulation. Although neither TWEAK nor TWEAKblocking reagents significantly effected apoptosis in macrophages and foam cells in vitro, apoptosis was enhanced with TWEAK plus TNF costimulation, and TWEAK plus cycloheximide, consistent with previous findings. 7,18 -20 However, no differences in apoptotic cell numbers were observed in the aortic arch sections between Fn14-Fc-treated and control mice. Assessment of apoptosis by TUNEL staining was only performed at the end-stage and potential effects in early plaque development could have been missed. However, the size of necrotic cores did not differ between Fn14-Fc-treated mice and controls. As it is assumed that lipid core size is in part determined by the extent of macrophage cell death and release of lipid contents within an atherosclerotic lesion, potential differences in apoptotic cell death attributable to Fn14-Fc treatment in an earlier phase of plaque development were not translated in differences in lipid core size.
Another possible explanation for the increased plaque macrophage content of Fn14-Fc-treated mice is modulation of cell migration. Our results revealed that blocking TWEAK enhanced cell migration in vitro. At first glance, this is unexpected, given that blocking TWEAK reduced cell infiltration into disease target tissue. 21, 22 However, in our in vitro system where the number of cells in the membrane is enhanced by anti-TWEAK, the cell number in the chambers is correspondingly reduced. Thus the in vitro system simply demonstrates the ability of the pathway to regulate macrophage trafficking and suggests that anti-TWEAK may alter the distribution of macrophages in vivo. The mechanism of action remains to be elucidated, but it may reflect that blocking TWEAK effects chemokine gradients and adhesion molecule expression, regulating where cells migrate and whether they are retained in the disease target tissue.
The smaller size of macrophages in lesions of Fn14-Fctreated mice led us to investigate the effects of TWEAK on lipid uptake by macrophages. Interestingly, blocking the TWEAK/Fn14 pathway significantly decreased oxLDL uptake compared to control antibody treatment. This decrease in lipid uptake was apparently not regulated by changes in CD36 and SR-A gene expression.
We also investigated the mechanism underlying reduced fibrotic content in advanced plaques from Fn14-Fc-treated ApoE Ϫ/Ϫ mice. TWEAK and Fn14 are expressed in SMCs of human carotid atherosclerotic plaques. 14 We found a significantly reduced SMC content in lesions of the Fn14-Fcdelayed treatment group suggesting that TWEAK/Fn14 interactions mediate SMC proliferation and migration in atherosclerosis, consistent with in vitro studies. 11, 23 We also showed reduced collagen in advanced plaques in Fc14-Fctreated mice even in the case of early treatment, where SMC content was similar in Fn14-Fc and control-treated mice, suggesting that Fn14-Fc also inhibited collagen production. Although further investigations are warranted to directly determine whether TWEAK/Fn14 signaling promotes collagen synthesis by SMCs, preliminary studies indicate that TWEAK can induce collagen synthesis by a liver stellate cell line (A. Jakubowski, Biogen Idec, personal communication 2009) and in human SMCs (S. Heeneman, Maastricht University, unpublished observations 2009). Regardless of the mechanism, our finding is novel, the first demonstration to our knowledge that blocking TWEAK can inhibit fibrosis.
TWEAK and Fn14 are widely recognized as an exclusive ligand-receptor pair and no other ligand for Fn14 has been identified, thus Fn14-Fc was used to block TWEAK binding and signaling through cell surface Fn14. Soluble Fn14 also appears to inhibit the recently reported TWEAK/CD163 interaction. 6, 24 The consequences of the unique advanced plaque phenotype resulting from Fn14-Fc treatment are unknown, and so the utility of targeting TWEAK with Fn14-Fc in atherosclerosis remains to be determined. Investigations to characterize the macrophage type, classical inflammatory or other, 25 resulting from Fn14-Fc treatment will shed further light on this topic. It will also be of interest to determine the effect of blocking TWEAK with an anti-TWEAK mAb in ApoE Ϫ/Ϫ mice, considering the precedence for differential efficacy of TNF inhibitors, the TNF-RII-Fc fusion protein, and anti-TNF mAbs. 26 The role of TNF␣ as compared to TWEAK in atherosclerosis is of considerable interest. TNF␣ exerts proinflammatory effects by binding to the receptors TNF-R1 (p55) or TNF-RII (p75) and mediates apoptosis through TNF-R1. In vivo studies on the role of the TNF␣ pathway in atherosclerosis using knockout mice in general point to a protective effect of TNF deletion or neutralization. Mice deficient in TNF␣ and ApoE showed reduced atherosclerosis development [27] [28] [29] that was mediated by TNF-RII (p75), 30 rather than TNF-RI (p55), 31 suggesting that the proinflammatory actions of soluble TNF␣ lead to more severe atherosclerosis. In our study of chow-fed ApoE Ϫ/Ϫ mice, Fn14-Fc presumably mediated scavenging of soluble TWEAK. TWEAK and TNF␣ have been reported to cooperatively stimulate inflammatory activity in various cell types 2 and may interplay in promoting atherosclerosis in ApoE Ϫ/Ϫ mice as well.
In summary, we have demonstrated that TWEAK/Fn14 interactions play a role in atherosclerosis. Fn14-Fc treatment to inhibit these interactions in ApoE Ϫ/Ϫ mice did not prevent the initiation of lesions, but delayed treatment resulted in advanced plaques that were reduced in size, number, and fibrotic content, and had an increased abundance of macrophages and reduced macrophage size, potentially by inhibiting lipid uptake. The mechanisms underlying these effects and the potential for therapeutic targeting of the TWEAK/ Fn14 pathway warrants further elucidation.
